[Physiology and pathophysiology of antibacterial phagocytosis. II. Pathophysiology].
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002609:Chediak-Higashi Syndrome / Q000503:physiopathology; D005260:Female; D005955:Glucosephosphate Dehydrogenase Deficiency; D006098:Granulocytes / Q000473:pathology; D006801:Humans; D007223:Infant; D017708:Leukocyte Transfusion; D008297:Male; D009195:Peroxidase / Q000172:deficiency; D010585:Phagocyte Bactericidal Dysfunction / Q000503:physiopathology / Q000628:therapy; D010586:Phagocytes / Q000473:pathology*; D010587:Phagocytosis; D013203:Staphylococcal Infections; D013290:Streptococcal Infections; D014184:Transplantation, Homologous
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D009195:Peroxidase
Physiologie und Pathophysiologie der antibakteriellen Phagozytose. II. Pathophysiologie